Vivos (RDGL) Cash & Equivalents Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -9.44% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 19.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -36.69% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 36.60% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 40.99% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 34.11% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.52% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -0.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 28.25% |
| 10 | Vivos | - | - | -3,105.00 | -2.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.97% |
| Sep 30, 2025 | 3.47% |
| Jun 30, 2025 | 36.30% |
| Mar 31, 2025 | 38.77% |
| Dec 31, 2024 | 11.27% |
| Sep 30, 2024 | -15.04% |
| Jun 30, 2024 | -7.30% |
| Mar 31, 2024 | -18.28% |
| Dec 31, 2023 | 20.78% |
| Sep 30, 2023 | 368.62% |
| Jun 30, 2023 | 91.54% |
| Dec 31, 2022 | 337.44% |
| Sep 30, 2022 | 132.31% |
| Jun 30, 2022 | 398.10% |
| Mar 31, 2022 | 208.07% |
| Dec 31, 2021 | 563.69% |
| Mar 31, 2021 | 5,294.58% |
| Dec 31, 2020 | 377.18% |
| Sep 30, 2020 | -12.26% |
| Jun 30, 2020 | -12.34% |
| Dec 31, 2019 | -9.93% |
| Sep 30, 2019 | 2,094.56% |
| Jun 30, 2019 | 259.49% |
| Mar 31, 2019 | -44.76% |
| Dec 31, 2018 | -68.69% |
| Mar 31, 2018 | -81.40% |
| Dec 31, 2017 | 244.74% |
| Sep 30, 2017 | 247.92% |
| Jun 30, 2017 | 43.42% |
| Mar 31, 2017 | -36.29% |
| Sep 30, 2016 | -91.70% |
| Jun 30, 2016 | -70.30% |
| Mar 31, 2016 | 54.28% |
| Dec 31, 2015 | 203.39% |
| Sep 30, 2015 | -46.16% |
| Jun 30, 2015 | 23.75% |
| Dec 31, 2014 | -84.31% |
| Sep 30, 2014 | -69.58% |
| Jun 30, 2014 | 190.06% |
| Sep 30, 2013 | -63.87% |
| Jun 30, 2013 | -48.56% |